Verseon Corporation Additional Listing & Total Voting Rights (1147M)

TIDMVSN

RNS Number : 1147M

Verseon Corporation

03 January 2019

January 3, 2019

Verseon Corporation

("Verseon" or the "Company")

Additional Listing & Total Voting Rights

Fremont, Calif.-Verseon, a technology-based pharmaceutical company, announces that application has been made for 11,389 new shares of common stock ("Common Shares") of par value US$0.001 each to be admitted to trading on AIM pursuant to regularly scheduled vesting of restricted stock units (the "Issuance").

The 11,389 new Common Shares issued pursuant to the Issuance will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on January 7, 2018 ("Admission").

Total Voting Rights

Following Admission, the issued share capital of the Company will consist of 151,695,038 Common Shares and the Company will hold 42,917 shares in treasury. Therefore, the total number of Common Shares in the Company with voting rights will be 151,652,121. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

 
 Verseon Corporation                              www.verseon.com 
 Sebastian Wykeham                                [phone] 
 
 Arden Partners (NOMAD and Joint Broker) 
 
 Ruari McGirr / Ciaran Walsh / Maria               [phone] 
  Gomez De Olea                                    5900 
 
 Cantor Fitzgerald Europe (Joint Broker) 
                                                  [phone] 
 Marc Milmo / Phil Davies / Callum Butterfield     7000 
 
 

For financial and business media enquiries, please contact

 
 Buchanan Communications Ltd (PR Advisers) 
                                              [phone] 
 Henry Harrison-Topham / Jamie Hooper          5000 
 

For trade and pharma media enquiries, please contact

 
 Vane Percy & Roberts 
                         [phone] 
 Simon Vane Percy         890 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCEAEFDEFLNEFF

(END) Dow Jones Newswires

January 03, 2019 05:20 ET (10:20 GMT)